• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioNTech SE - American Depositary Shares (NQ:BNTX)

110.14 -0.28 (-0.25%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 946,245
Open 109.19
Bid (Size) 106.10 (100)
Ask (Size) 111.37 (100)
Prev. Close 110.42
Today's Range 108.65 - 110.89
52wk Range 81.20 - 124.00
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
February 17, 2026
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
February 17, 2026
As of February 17, 2026, Moderna, Inc. (NASDAQ:MRNA) finds itself at a pivotal crossroads in its corporate evolution. Long defined by its meteoric rise during the COVID-19 pandemic, the Cambridge-based... 
Via Finterra
Topics Economy Intellectual Property

Performance

YTD
+13.9%
+13.9%
1 Month
-6.7%
-6.7%
3 Month
+15.2%
+15.2%
6 Month
-0.7%
-0.7%
1 Year
-6.6%
-6.6%

More News

Read More
BNTX Shares Rise On Goldman Sachs Upgrade, Optimism For Cancer Portfolio ↗
January 16, 2026
Via Stocktwits
News headline image
Moderna (MRNA) Deep Dive: Navigating Regulatory Blows and the Pivot to Oncology
February 11, 2026
Via Finterra
Topics Artificial Intelligence Initial Public Offering Intellectual Property
News headline image
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
January 28, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
2 Biotech Stocks Set to Rebound in 2026 ↗
January 27, 2026
Via The Motley Fool
News headline image
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally
January 22, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
January 22, 2026
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy Era
January 14, 2026
From USA News Group
Via GlobeNewswire
News headline image
Moderna’s High-Stakes Transformation: Navigating the Post-Pandemic Pivot
January 14, 2026
Via Finterra
Topics Initial Public Offering Intellectual Property
Trump’s Iran Tariff Threat Lit a Fuse Under Oil — and Wall Street Still Sold It ↗
January 14, 2026
Via Chartmill
Topics Government
News headline image
The mRNA Pivot: Moderna Navigates Regulatory Headwinds and Tariff Turmoil in a Volatile 2026 Biotech Landscape
January 12, 2026
Via MarketMinute
Topics Economy Intellectual Property World Trade
News headline image
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
January 12, 2026
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Finalizes CureVac Acquisition: A Strategic Consolidation Met with Market Skepticism
January 09, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics
January 09, 2026
Via PredictStreet
Topics Initial Public Offering Intellectual Property
News headline image
Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge
January 07, 2026
Via PredictStreet
Topics Economy Initial Public Offering Intellectual Property
News headline image
Genmab Stock Slips After Discontinuing Further Development Of Cancer Drug Developed With BioNTech ↗
December 29, 2025
Via Stocktwits
Topics Supply Chain
News headline image
Moderna (MRNA) Deep-Dive: Navigating the 7.5% Year-End Slide and the Path to a 2028 Recovery
December 24, 2025
Via PredictStreet
Topics Initial Public Offering
News headline image
The Pfizer Pivot: A Deep-Dive into PFE’s 2025 Financial Recovery and Strategic Rebirth
December 22, 2025
Via PredictStreet
Topics Economy Intellectual Property
News headline image
Moderna (MRNA): The “Act 2” of an mRNA Pioneer – A 2025 Deep Dive
December 22, 2025
Via PredictStreet
Topics Earnings Initial Public Offering Intellectual Property
News headline image
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
December 18, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
Pfizer's Muted 2026 Outlook Sends Ripples Through Pharmaceutical Sector
December 16, 2025
Via MarketMinute
Topics Intellectual Property
News headline image
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
December 09, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
December 06, 2025
From BioNTech SE
Via GlobeNewswire
News headline image
BioNTech Achieves Minimum Condition in CureVac Exchange Offer
December 03, 2025
From BioNTech SE
Via GlobeNewswire

Frequently Asked Questions

Is BioNTech SE - American Depositary Shares publicly traded?
Yes, BioNTech SE - American Depositary Shares is publicly traded.
What exchange does BioNTech SE - American Depositary Shares trade on?
BioNTech SE - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for BioNTech SE - American Depositary Shares?
The ticker symbol for BioNTech SE - American Depositary Shares is BNTX on the Nasdaq Stock Market
What is the current price of BioNTech SE - American Depositary Shares?
The current price of BioNTech SE - American Depositary Shares is 110.14
When was BioNTech SE - American Depositary Shares last traded?
The last trade of BioNTech SE - American Depositary Shares was at 02/20/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap